Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Considering taking supplements to treat aromatase inhibitor induced arthralgia? Below is a list of common natural remedies used to treat or reduce the symptoms of aromatase inhibitor induced ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

Aromatase inhibition could be an alternative to testosterone administration to mitigate declining androgen production in hypogonadal older men. Unlike testosterone replacement, aromatase ...